MyFinsight
Home
Blog
About
Net earnings (loss)
-$58,371K
(-359.44%↓ Y/Y)
Interest and other
income, net
$2,630K
(-41.92%↓ Y/Y)
Qelbree
$89,239K
(15.08%↑ Y/Y)
GOCOVRI
$37,530K
(2.37%↑ Y/Y)
ONAPGO
$13,546K
(744.51%↑ Y/Y)
Oxtellar XR
$8,782K
(-24.53%↓ Y/Y)
Trokendi Xr
$8,411K
(-24.85%↓ Y/Y)
APOKYN
$6,323K
(-50.68%↓ Y/Y)
Manufactured Product Other
$1,882K
(-71.20%↓ Y/Y)
Earnings (loss) before
income taxes
-$57,648K
(-445.84%↓ Y/Y)
Income tax expense
(benefit)
$723K
(112.40%↑ Y/Y)
Total other income,
net
$315K
(-93.04%↓ Y/Y)
Product
$165,713K
(4.88%↑ Y/Y)
Collaboration Revenue
$35,350K
Royalty License And
Other Revenue
$17,995K
(141.28%↑ Y/Y)
Interest expense
$2,315K
Operating earnings (loss)
-$57,963K
(-577.42%↓ Y/Y)
Total revenues
$219,058K
(32.40%↑ Y/Y)
Total costs and
expenses
$277,021K
(80.69%↑ Y/Y)
Selling, general and
administrative
$133,637K
(42.85%↑ Y/Y)
Intangible asset
impairment charges
$54,919K
Cost of revenues
$33,669K
(100.09%↑ Y/Y)
Research and development
$29,463K
(33.23%↑ Y/Y)
Amortization of intangible
assets
$25,333K
(21.68%↑ Y/Y)
Back
Back
Income Statement
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
source: myfinsight.com